AbbVie Gets European OK of Rinvoq in Atopic Dermatitis
August 24 2021 - 8:41AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Tuesday said the European Commission approved
expanded use of its JAK inhibitor Rinvoq for the treatment of
moderate to severe atopic dermatitis in patients 12 years and older
who are candidates for systemic therapy.
The North Chicago, Ill., biopharmaceutical company said the
approval is based on Phase 3 studies in which Rinvoq showed rapid
and significant improvement in skin clearance and itch
reduction.
AbbVie said Rinvoq is the first JAK inhibitor approved in the
European Union for the treatment of both adults and adolescents
with moderate to severe atopic dermatitis, the most common form of
the inflammatory skin disease eczema.
European regulators had previously approved Rinvoq in rheumatoid
arthritis, psoriatic arthritis and ankylosing spondylitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 24, 2021 08:33 ET (12:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2024 to May 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2023 to May 2024
